Moderate

Membranous nephropathy (membranous glomerulonephritis)

Glomerular disease · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Commonest cause of primary nephrotic syndrome in (especially older, Caucasian) adults. Subepithelial immune-complex deposits thicken the GBM. ~70-80% are primary/autoimmune, most driven by anti-phospholipase A2 receptor (anti-PLA2R) antibodies (also anti-THSD7A); the rest are secondary (malignancy, SLE class V, HBV, drugs such as NSAIDs/penicillamine). Presents with nephrotic syndrome and carries the HIGHEST thromboembolic risk of the glomerular diseases (renal vein thrombosis, PE). Management is risk-stratified: supportive care for low risk, immunosuppression (rituximab-led) for moderate/high risk.

Red flags

  • Sudden loin pain, haematuria and GFR fall — renal vein thrombosis (classic in membranous)
  • Pleuritic chest pain/dyspnoea — pulmonary embolism
  • Rapidly rising creatinine — superimposed crescentic GN (anti-GBM can complicate MN) or ATN; re-biopsy
  • New membranous in an older adult — exclude underlying malignancy
  • Severe refractory nephrotic syndrome with complications

Assessment

Differential diagnosis

  • Minimal change / FSGS (nephrotic syndrome)
  • Diabetic nephropathy; amyloidosis
  • Lupus membranous (class V) nephritis
  • Secondary membranous: solid-organ malignancy (lung, GI, prostate), HBV, drugs (NSAIDs, penicillamine, gold)
  • Membranoproliferative GN

Investigations

  • Urine PCR/ACR + microscopy; serum albumin, U&E/creatinine/eGFR, lipids
  • Serum anti-PLA2R antibody (diagnostic and used to monitor immunological activity) +/- anti-THSD7A
  • Secondary screen: ANA/dsDNA + complement (lupus), HBV/HCV/HIV, age-appropriate malignancy screening (particularly if PLA2R-negative/older), drug review
  • Renal biopsy (light microscopy GBM thickening/'spikes', granular IgG + C3 on immunofluorescence, subepithelial deposits on EM); PLA2R staining on tissue
  • Thrombosis assessment; imaging (Doppler/CT) if renal vein thrombosis/PE suspected

Management

  • Confirm on biopsy and serology (anti-PLA2R); actively exclude secondary causes (malignancy screen in older/PLA2R-negative patients, lupus, HBV, drugs)
  • Start maximal supportive/antiproteinuric therapy in all: ACEi/ARB, BP control, statin, sodium restriction, diuretics for oedema — and observe, as spontaneous remission occurs in a proportion
  • Risk-stratify (KDIGO) by proteinuria level/trend, serum albumin, eGFR trajectory and anti-PLA2R titre into low / moderate / high / very-high risk
  • Low risk: continue supportive therapy and monitor (many remit)
  • Moderate-to-high risk: immunosuppression — rituximab is first-line (MENTOR trial: superior sustained remission vs ciclosporin); alternatives are cyclical steroid + cyclophosphamide (Ponticelli) or a calcineurin inhibitor
  • Very-high risk (rapidly declining eGFR, severe/complicated nephrotic syndrome): alternating corticosteroid + cyclophosphamide
  • Address the high VTE risk: prophylactic anticoagulation when serum albumin is low (commonly <20-25 g/L and additional risk factors; KDIGO suggests considering warfarin when albumin <~25 g/L in primary MN) and full anticoagulation for confirmed thrombosis
  • Monitor anti-PLA2R titre as a marker of immunological remission (falls before proteinuria) and surveil renal function

Drugs & doses

Ramipril 2.5-10 mg PO once daily OR losartan 50-100 mg PO once daily (antiproteinuric) [verify local dose]
Atorvastatin 20-40 mg PO once daily
Furosemide 40-80 mg PO/IV for oedema [verify local dose]
Rituximab (e.g. 1 g IV x2 doses 2 weeks apart, or 375 mg/m2 weekly x4) for moderate/high-risk disease — specialist-initiated [verify local dose]
Modified Ponticelli regimen: alternating monthly IV/oral methylprednisolone and oral cyclophosphamide over 6 months (very-high/high risk) [verify local dose]
Calcineurin inhibitor (tacrolimus/ciclosporin) as alternative immunosuppression [verify local dose]
Prophylactic anticoagulation when albumin low (warfarin target INR 2-3, or LMWH enoxaparin 40 mg SC once daily); therapeutic anticoagulation for confirmed renal vein thrombosis/PE [verify local threshold/dose]

Disposition

Nephrology outpatient with biopsy/serology-directed, risk-stratified therapy. Admit for thromboembolism, rapid GFR decline or severe nephrotic complications. Long-term monitoring of proteinuria, eGFR and anti-PLA2R.

Complications & pitfalls

  • Thromboembolism — highest of all glomerular diseases (renal vein thrombosis, DVT/PE, arterial events)
  • Progression to CKD/ESKD in a subset; others remit spontaneously
  • Infection and hyperlipidaemia (nephrotic)
  • Immunosuppression toxicity (infection, malignancy, gonadotoxicity with cyclophosphamide)
  • Underlying malignancy in secondary cases

Exam pearls

  • Anti-PLA2R antibody is the game-changer: positive serology supports primary MN, can sometimes avoid biopsy, and the titre tracks disease activity (falls before proteinuria improves) to guide therapy.
  • KDIGO risk-based management: observe/supportive for low risk (spontaneous remission is common), rituximab-led immunosuppression for moderate-high risk (MENTOR), cyclophosphamide-steroid for very-high risk.
  • Membranous carries the highest thrombosis risk of the glomerulonephritides — have a low threshold for prophylactic anticoagulation when albumin is low, and always image loin pain/GFR drop for renal vein thrombosis.
  • In older or PLA2R-negative patients, screen for occult malignancy before labelling it primary.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.